---
document_datetime: 2026-01-27 10:30:31
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/avzivi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: avzivi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.1510914
conversion_datetime: 2026-01-29 12:43:22.154682
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Avzivi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | A. ADMINISTRATIVE CHANGES - A.z Other | 15/01/2026                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000322804                     | variation - Refused                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000293189 | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.a.3 Change in batch size (including batch | 27/11/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                            | intermediate used in the manufacturing process of the active substance - B.I.a.3.c The change requires assessment of the comparability of a biological/immunological active substance - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted   |            |            |      |           |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------|
| PSUR / EMA/PSUR/0000274402 | - - In view of available data on hyaline occlusive glomerular microangiopathy reported in the literature, including in some cases a positive de-challenge and in view of a plausible mechanism of action, the PRAC considers a causal relationship between bevacizumab and hyaline occlusive glomerular microangiopathy is at least a reasonable possibility. The PRAC concluded that the                                                                                                                                                                                                                                                                    | 16/10/2025 | 18/12/2025 | SmPC | Variation |

<div style=\"page-break-after: always\"></div>

| product information of products containing bevacizumab should be amended accordingly.   |
|-----------------------------------------------------------------------------------------|